DelveInsight’s, “Peritoneal Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Peritoneal Cancer Understanding
Peritoneal Cancer: Overview
Peritoneal cancer is is a rare form of cancer affecting the peritoneum, the thin membrane surrounding your abdominal organs. The causes of peritoneal cancer are unknown. Primary peritoneal cancer is more common in women than in men. The symptoms of peritoneal cancer resemble those of ovarian cancer. Many of these symptoms are due to buildup of fluid (ascites) in the abdomen. Peritoneal cancer symptoms may include: nausea, loss of appetite, vomiting, abnormal vaginal bleeding, rectum bleeding, feeling of fullness after breath and shortness of breath. Physical exam, Ultrasound, medical history are some procedures followed up for the diagnosis of peritoneal cancer. The treatment usually depends upon the size, location and stage of cancer.

"Peritoneal Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal Cancer pipeline landscape is provided which includes the disease overview and Peritoneal Cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
● The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

Peritoneal Cancer Emerging Drugs Chapters
This segment of the Peritoneal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peritoneal Cancer Emerging Drugs
● Mirvetuximab Soravtansine: ImmunoGen
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with peritoneal cancer.

● Entinostat: Syndax Pharmaceuticals
Entinostat, is a selective, oral, once-weekly, class I HDAC inhibitor that has been studied in multiple solid tumors in combination with hormone therapy and several approved PD-1/PD-L1 antagonists. The drug is in phase I/II stage for the treatment of peritoneal cancer.
Further product details are provided in the report……..

Peritoneal Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Peritoneal Cancer drugs segregated based on following parameters that define the scope of the report, such as:
● Major Players in Peritoneal Cancer
There are approx. 15+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. phase III include, Immunogen.
● Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration
Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
● Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal Cancer drugs.

Peritoneal Cancer Report Insights
• Peritoneal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritoneal Cancer Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Peritoneal Cancer drugs?
• How many Peritoneal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peritoneal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritoneal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?